PL345577A1 - Inhibitors of transcription factor nf-κb - Google Patents

Inhibitors of transcription factor nf-κb

Info

Publication number
PL345577A1
PL345577A1 PL99345577A PL34557799A PL345577A1 PL 345577 A1 PL345577 A1 PL 345577A1 PL 99345577 A PL99345577 A PL 99345577A PL 34557799 A PL34557799 A PL 34557799A PL 345577 A1 PL345577 A1 PL 345577A1
Authority
PL
Poland
Prior art keywords
inhibitors
transcription factor
transcription
factor
Prior art date
Application number
PL99345577A
Inventor
James F Callahan
Marie C Chabot-Fletcher
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of PL345577A1 publication Critical patent/PL345577A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4462—Non condensed piperidines, e.g. piperocaine only substituted in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • AIDS & HIV (AREA)
PL99345577A 1998-06-19 1999-06-18 Inhibitors of transcription factor nf-κb PL345577A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9001698P 1998-06-19 1998-06-19
PCT/US1999/013897 WO1999065495A1 (en) 1998-06-19 1999-06-18 INHIBITORS OF TRANSCRIPTION FACTOR NF-λB

Publications (1)

Publication Number Publication Date
PL345577A1 true PL345577A1 (en) 2001-12-17

Family

ID=22220761

Family Applications (1)

Application Number Title Priority Date Filing Date
PL99345577A PL345577A1 (en) 1998-06-19 1999-06-18 Inhibitors of transcription factor nf-κb

Country Status (17)

Country Link
EP (1) EP1085872A4 (en)
JP (1) JP2002518333A (en)
KR (1) KR20010052990A (en)
CN (1) CN1306428A (en)
AR (1) AR019871A1 (en)
AU (1) AU4699699A (en)
BR (1) BR9911151A (en)
CA (1) CA2335293A1 (en)
CO (1) CO5080752A1 (en)
CZ (1) CZ20004760A3 (en)
HU (1) HUP0102492A2 (en)
IL (1) IL140324A0 (en)
NO (1) NO20006452L (en)
PL (1) PL345577A1 (en)
TR (1) TR200003779T2 (en)
WO (1) WO1999065495A1 (en)
ZA (1) ZA200007448B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999058674A2 (en) 1998-05-14 1999-11-18 Immunex Corporation Method of inhibiting osteoclast activity
ATE497001T1 (en) 1996-12-23 2011-02-15 Immunex Corp RECEPTOR ACTIVATOR OF NF-KAPPA B, RECEPTOR IS A MEMBER OF THE TNF RECEPTOR SUPERFAMILY
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
AU2968701A (en) * 2000-01-24 2001-07-31 Genzyme Corporation Jak/stat pathway inhibitors and the uses thereof
US20060148732A1 (en) * 2000-11-17 2006-07-06 Gutterman Jordan U Inhibition of NF-kappaB by triterpene compositions
TR201809678T4 (en) 2001-06-26 2018-07-23 Amgen Fremont Inc Antibodies against opgl.
US7425580B2 (en) 2004-05-19 2008-09-16 Wyeth (Diaryl-methyl)-malononitriles and their use as estrogen receptor ligands
WO2007097981A2 (en) 2006-02-16 2007-08-30 Millennium Pharmaceuticals, Inc. Alpha carbolines and uses thereof
EP2366699B1 (en) 2008-10-02 2013-08-07 Asahi Kasei Pharma Corporation 8-substituted isoquinoline derivative and use thereof
WO2010108058A2 (en) 2009-03-20 2010-09-23 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Small molecule inhibitors of dusp6 and uses therefor
US9186365B2 (en) * 2009-07-31 2015-11-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antiangiogenic small molecules and methods of use
WO2012109527A2 (en) 2011-02-10 2012-08-16 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Class of hdac inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury
US9670236B2 (en) 2012-10-31 2017-06-06 University of Pittsburgh—of the Commonwealth System of Higher Education Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury

Also Published As

Publication number Publication date
TR200003779T2 (en) 2001-06-21
IL140324A0 (en) 2002-02-10
CN1306428A (en) 2001-08-01
AU4699699A (en) 2000-01-05
ZA200007448B (en) 2001-12-12
NO20006452D0 (en) 2000-12-18
EP1085872A1 (en) 2001-03-28
KR20010052990A (en) 2001-06-25
CZ20004760A3 (en) 2001-08-15
BR9911151A (en) 2001-03-06
JP2002518333A (en) 2002-06-25
CO5080752A1 (en) 2001-09-25
AR019871A1 (en) 2002-03-20
EP1085872A4 (en) 2003-04-16
HUP0102492A2 (en) 2001-11-28
NO20006452L (en) 2001-02-16
CA2335293A1 (en) 1999-12-23
WO1999065495A1 (en) 1999-12-23

Similar Documents

Publication Publication Date Title
PL348969A1 (en) Inhibitors of transcription factor nf-κb
PL327569A1 (en) Promedications of thrombosin inhibitors
PL334846A1 (en) Sulphamidic inhibitors of metaloproteases
HU9602516D0 (en) Isoprenyl transferase inhibitors
GB9611422D0 (en) Coated scale inhibitors
PL333918A1 (en) Derivatives of 6-phenylpyryidil-2-amine useful as nos inhibitors
IL137540A0 (en) Inhibitors of phospholipase a2
AU6229699A (en) Beta-amyloid formation inhibitors
HUP9700602A3 (en) New inhibitors of bone-resorption and vitronectine-receptor-antagonists
IL143535A0 (en) Inhibitors of multidrug transporters
PL331920A1 (en) Spirocyclic inhibitors of metaloproteases
PL331803A1 (en) Bidonoric metaloprotease inhibitors
AU692123B2 (en) 5alpha-reductase inhibitors
AU5599598A (en) Inhibitors of glycosyltransferases
IL140324A0 (en) Inhibition of transcription factor nf-kb
AU2277597A (en) New inhibitors of sh2-mediated processes
AU5673099A (en) Inhibitors of amyloid formation
ZA9710989B (en) Polyprolyl inhibitors of cyclophilin
AU6678398A (en) Inhibitors of isoprenyl transferase
IL134210A0 (en) Use of transcription factor brn-3a
AU5126298A (en) Inhibition of crib-biting
HK1035667A (en) INHIBITORS OF TRANSCRIPTION FACTOR NF-κB
HK1035668A (en) INHIBITORS OF TRANSCRIPTION FACTOR NF-κB
AU4021700A (en) Methods of use of beta1-integrin inhibitors
AU1143200A (en) Polymorphic forms of an amyloidosis inhibitor and methods of preparation

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)